Skip to main content

Trails Edge Capital Partners, LP

13F filer · CIK 0002077247
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$630MU.S. long equity reported on 13F
Positions3513 new · 4 closed
Net flow last quarter+$63.1MBuys minus sells
Top 10 positions weight50.3%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202635 positions
LBRXLB Pharmaceuticals Inc$49.4M7.85%5.31%+15.4%Q4 2025
NRIXNurix Therapeutics, Inc.$38.2M6.06%1.52%-9.8%Q4 2025
IMCRImmunocore Holdings plc$33.8M5.36%2.07%+55.8%Q4 2025
TRAXFirst Tracks Biotherapeutics, Inc.$30.5M4.84%4.28%NewQ2 2026
FDMT4D Molecular Therapeutics, Inc.$29.6M4.70%4.04%+71.0%Q1 2026
BMRNBiomarin Pharmaceutical Inc$29.3M4.65%0.26%NewQ2 2026
DSGNDesign Therapeutics, Inc.$29M4.60%3.20%+134.9%Q1 2026
XENEXenon Pharmaceuticals Inc.$26.6M4.22%0.45%Not reportedQ4 2025
MIRMMirum Pharmaceuticals, Inc.$26.1M4.15%0.34%-33.0%Q4 2025
INSMINSMED Inc$24.6M3.90%0.11%NewQ2 2026
CYTKCytokinetics Inc$24.5M3.90%0.23%-4.0%Q1 2026
SNDXSyndax Pharmaceuticals Inc$24.3M3.85%1.25%+58.2%Q1 2026
NGNENeurogene Inc.$22.5M3.57%4.52%-8.7%Q4 2025
KLRAKailera Therapeutics, Inc.$21.7M3.44%0.76%NewQ2 2026
RVMDRevolution Medicines, Inc.$21.7M3.44%0.05%-52.8%Q1 2026
IKTInhibikase Therapeutics, Inc.$18.4M2.92%6.86%+12.3%Q4 2025
INCYIncyte Corp$17.6M2.79%0.08%NewQ2 2026
AVTXAvalo Therapeutics, Inc.$16.5M2.62%1.69%NewQ2 2026
MLTXMoonLake Immunotherapeutics$14.6M2.32%1.02%NewQ2 2026
FTHFaeth Therapeutics, Inc.$12.9M2.05%1.99%+312.3%Q1 2026
XFORX4 Pharmaceuticals, Inc$12M1.91%2.68%Not reportedQ4 2025
IRDOpus Genetics, Inc.$11.3M1.79%3.32%+448.7%Q1 2026
SLGLSol-Gel Technologies Ltd.$10.3M1.64%5.00%+63.1%Q1 2026
AURAAura Biosciences, Inc.$10.2M1.63%1.39%NewQ2 2026
IPSCCentury Therapeutics, Inc.$10.1M1.61%2.29%+68.8%Q1 2026
IVAInventiva S.A.$10M1.60%1.38%Not reportedQ4 2025
CAMPCamp4 Therapeutics Corp$8.45M1.34%3.72%-0.3%Q4 2025
ALTAltimmune, Inc.$8.09M1.28%1.37%NewQ2 2026
NERVMinerva Neurosciences, Inc.$7.88M1.25%3.00%Not reportedQ1 2026
PMNProMIS Neurosciences Inc.$7.33M1.16%6.21%Not reportedQ1 2026
OKUROnKure Therapeutics, Inc.$6.56M1.04%3.56%NewQ2 2026
FBRXForte Biosciences, Inc.$5.81M0.92%1.33%NewQ2 2026
RACCResearch Alliance Corp III$5.35M0.85%Not reportedNewQ2 2026
VTVTvTv Therapeutics Inc.$3.21M0.51%Not reported-39.0%Q4 2025
IMAImageneBio, Inc.$1.66M0.26%2.50%NewQ2 2026
Q1 2026Reported May 15, 202626 positions
PCVXVaxcyte, Inc.$38.5M8.82%0.46%-10.2%Q4 2025
DFTXDefinium Therapeutics, Inc.$32.9M7.53%1.67%NewQ1 2026
LBRXLB Pharmaceuticals Inc$32.5M7.45%4.60%-5.5%Q4 2025
MIRMMirum Pharmaceuticals, Inc.$30.8M7.05%0.55%+946.1%Q4 2025
NRIXNurix Therapeutics, Inc.$27M6.19%1.69%Not reportedQ4 2025
XENEXenon Pharmaceuticals Inc.$25.6M5.86%0.46%-26.3%Q4 2025
RVMDRevolution Medicines, Inc.$23.8M5.46%0.12%NewQ1 2026
RCUSArcus Biosciences, Inc.$22.6M5.19%0.84%+14.4%Q4 2025
IMCRImmunocore Holdings plc$20.6M4.71%1.34%Not reportedQ4 2025
CYTKCytokinetics Inc$19.8M4.53%0.24%NewQ1 2026
SNDXSyndax Pharmaceuticals Inc$16.4M3.76%0.79%NewQ1 2026
NGNENeurogene Inc.$15.8M3.62%5.01%-0.3%Q4 2025
IVAInventiva S.A.$14.8M3.38%1.38%Not reportedQ4 2025
IKTInhibikase Therapeutics, Inc.$13.5M3.10%6.10%+30.4%Q4 2025
FDMT4D Molecular Therapeutics, Inc.$12.1M2.78%2.49%NewQ1 2026
XFORX4 Pharmaceuticals, Inc$10.6M2.43%2.73%Not reportedQ4 2025
IMVTImmunovant, Inc.$10.3M2.36%0.20%+72.4%Q4 2025
DSGNDesign Therapeutics, Inc.$9.07M2.08%1.36%NewQ1 2026
CAMPCamp4 Therapeutics Corp$8.55M1.96%3.74%-2.2%Q4 2025
NERVMinerva Neurosciences, Inc.$8.55M1.96%3.24%NewQ1 2026
PMNProMIS Neurosciences Inc.$7.08M1.62%6.21%NewQ1 2026
SLGLSol-Gel Technologies Ltd.$6.77M1.55%3.07%NewQ1 2026
IPSCCentury Therapeutics, Inc.$5.54M1.27%1.36%NewQ1 2026
VTVTvTv Therapeutics Inc.$5.54M1.27%Not reported-39.6%Q4 2025
FTHFaeth Therapeutics, Inc.$3.94M0.90%9.33%NewQ1 2026
IRDOpus Genetics, Inc.$2.28M0.52%0.70%NewQ1 2026
Q4 2025Reported Feb 17, 202623 positions
ACADAcadia Pharmaceuticals Inc$37.9M9.37%0.83%NewQ4 2025
MNMDDefinium Therapeutics, Inc.$34.4M8.50%Not reportedNewQ4 2025
PCVXVaxcyte, Inc.$34M8.41%0.56%NewQ4 2025
NRIXNurix Therapeutics, Inc.$33.1M8.17%1.71%NewQ4 2025
LBRXLB Pharmaceuticals Inc$31.1M7.68%5.52%NewQ4 2025
XENEXenon Pharmaceuticals Inc.$26.8M6.61%0.75%NewQ4 2025
IMCRImmunocore Holdings plc$23.7M5.85%1.35%NewQ4 2025
RCUSArcus Biosciences, Inc.$21.8M5.40%0.73%NewQ4 2025
TYRATyra Biosciences, Inc.$18.4M4.55%1.30%NewQ4 2025
NGNENeurogene Inc.$16.2M4.00%5.07%NewQ4 2025
FOLDAmicus Therapeutics, Inc.$14.9M3.67%0.34%NewQ4 2025
APGEApogee Therapeutics, Inc.$14.5M3.58%0.28%NewQ4 2025
IKTInhibikase Therapeutics, Inc.$12.7M3.13%4.69%NewQ4 2025
IVAInventiva S.A.$12.4M3.05%1.38%NewQ4 2025
CAMPCamp4 Therapeutics Corp$12.2M3.00%3.82%NewQ4 2025
TERNTerns Pharmaceuticals, Inc.$12.1M2.99%0.27%NewQ4 2025
XFORX4 Pharmaceuticals, Inc$10.3M2.54%2.83%NewQ4 2025
MBXMBX Biosciences, Inc.$9.94M2.46%0.70%NewQ4 2025
VTVTvTv Therapeutics Inc.$9.24M2.28%Not reportedNewQ4 2025
CMPXCompass Therapeutics, Inc.$7.6M1.88%0.79%NewQ4 2025
IMVTImmunovant, Inc.$6.1M1.51%0.12%NewQ4 2025
ELVNEnliven Therapeutics, Inc.$3.07M0.76%0.34%NewQ4 2025
MIRMMirum Pharmaceuticals, Inc.$2.52M0.62%0.06%NewQ4 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.